Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1998 1
1999 2
2000 5
2001 2
2002 1
2003 1
2004 1
2005 2
2006 2
2007 4
2008 4
2009 3
2010 6
2011 6
2012 7
2013 12
2014 18
2015 12
2016 14
2017 13
2018 14
2019 20
2020 10
2021 12
2022 7
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
Joseph NS, Kaufman JL, Dhodapkar MV, Hofmeister CC, Almaula DK, Heffner LT, Gupta VA, Boise LH, Lonial S, Nooka AK. Joseph NS, et al. Among authors: hofmeister cc. J Clin Oncol. 2020 Jun 10;38(17):1928-1937. doi: 10.1200/JCO.19.02515. Epub 2020 Apr 16. J Clin Oncol. 2020. PMID: 32298201 Free PMC article.
Daratumumab in multiple myeloma.
Nooka AK, Kaufman JL, Hofmeister CC, Joseph NS, Heffner TL, Gupta VA, Sullivan HC, Neish AS, Dhodapkar MV, Lonial S. Nooka AK, et al. Among authors: hofmeister cc. Cancer. 2019 Jul 15;125(14):2364-2382. doi: 10.1002/cncr.32065. Epub 2019 Apr 5. Cancer. 2019. PMID: 30951198 Free article. Review.
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.
Robinson MH, Villa NY, Jaye DL, Nooka AK, Duffy A, McCachren SS, Manalo J, Switchenko JM, Barnes S, Potdar S, Azeem MI, Horvat AA, Parihar VC, Gong J, Liang Y, Smith GH, Gupta VA, Boise LH, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Dhodapkar KM, Dhodapkar MV. Robinson MH, et al. Among authors: hofmeister cc. J Clin Invest. 2023 Aug 1;133(15):e167629. doi: 10.1172/JCI167629. J Clin Invest. 2023. PMID: 37526080 Free PMC article.
The potential of miRNAs as biomarkers for multiple myeloma.
Rocci A, Hofmeister CC, Pichiorri F. Rocci A, et al. Among authors: hofmeister cc. Expert Rev Mol Diagn. 2014 Nov;14(8):947-59. doi: 10.1586/14737159.2014.946906. Epub 2014 Aug 7. Expert Rev Mol Diagn. 2014. PMID: 25098410 Review.
Venetoclax ex vivo functional profiling predicts improved progression-free survival.
Gupta VA, Matulis SM, Barwick BG, Bog RD, Shebelut CW, Shanmugam M, Neri P, Bahlis NJ, Dhodapkar MV, Heffner LT, Hofmeister CC, Joseph NS, Lonial S, Kaufman JL, Jaye DL, Nooka AK, Boise LH. Gupta VA, et al. Among authors: hofmeister cc. Blood Cancer J. 2022 Aug 4;12(8):115. doi: 10.1038/s41408-022-00710-9. Blood Cancer J. 2022. PMID: 35927247 Free PMC article. No abstract available.
Most multiple myeloma patients have low testosterone.
John S, Sharma N, Sborov DW, Williams N, Jones D, Benson DM, Efebera YA, Rosko AE, Vincent J, Hofmeister CC. John S, et al. Among authors: hofmeister cc. Leuk Lymphoma. 2019 Mar;60(3):836-838. doi: 10.1080/10428194.2018.1508664. Epub 2018 Oct 2. Leuk Lymphoma. 2019. PMID: 30277092 Free PMC article. No abstract available.
Tocilizumab for steroid refractory acute graft-versus-host disease.
Roddy JV, Haverkos BM, McBride A, Leininger KM, Jaglowski S, Penza S, Klisovic R, Blum W, Vasu S, Hofmeister CC, Benson DM, Andritsos LA, Devine SM, Efebera YA. Roddy JV, et al. Among authors: hofmeister cc. Leuk Lymphoma. 2016;57(1):81-5. doi: 10.3109/10428194.2015.1045896. Epub 2015 Jul 3. Leuk Lymphoma. 2016. PMID: 26140610 Free PMC article.
164 results